Spinogenix
Clinical trials sponsored by Spinogenix, explained in plain language.
-
Alzheimer's drug SPG302 safety study ends early
Disease control TerminatedThis study aimed to check the long-term safety and effects of a daily pill called SPG302 in people with mild-to-moderate Alzheimer's disease. It included 12 participants who had already been in a previous SPG302 study. The study was terminated early, so results are limited.
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
ALS pill trial halted: what we know about SPG302's Long-Term safety
Disease control TerminatedThis study looked at the long-term safety and effectiveness of a daily oral medication called SPG302 in people with ALS who had already taken part in an earlier study. The trial was stopped early, and only 16 people were enrolled. Researchers tracked side effects, suicidal though…
Phase: PHASE2 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC